Yamauchi Keijiro, Komuta Riiko, Tanabe Hidetaka, Yokoyama Masashi, Takata S O, Yanase Takafumi, Hosono Yuki, Satoh Shingo, Morishita Naoko, Suzuki Hidekazu
Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan
Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.
Anticancer Res. 2025 Jan;45(1):369-378. doi: 10.21873/anticanres.17425.
BACKGROUND/AIM: The clinical benefits of durvalumab consolidation therapy following concurrent chemoradiotherapy (CCRT) with daily low-dose carboplatin in elderly patients with unresectable, locally advanced non-small cell lung cancer (NSCLC) remain unclear.
This was a single-institution retrospective cohort study. We analyzed the medical records of consecutive patients diagnosed with NSCLC who received CCRT with daily low-dose carboplatin from April 2014 to March 2021. Outcomes were compared between the overall group and two subgroups: those who received durvalumab consolidation therapy (CCRT-durvalumab group) and those who did not (CCRT-alone group). The primary endpoints were progression-free survival (PFS) and overall survival (OS).
A total of 38 patients (median age: 76 years) were enrolled in this study. The median PFS was 9.9 months in the overall group, 11.7 months in the CCRT-durvalumab group, and 10.2 months in the CCRT-alone group. The median OS was 39.4 months in the overall group, 32.0 months in the CCRT-durvalumab group, and 39.4 months in the CCRT-alone group. There were no significant differences between the two subgroups in terms of PFS [hazard ratio (HR)=0.88, p=0.97] or OS (HR=1.21, p=0.70).
In real-world settings, durvalumab consolidation therapy following CCRT with daily low-dose carboplatin does not appear to provide clinical benefits in terms of PFS or OS for elderly patients with unresectable, locally advanced NSCLC.
背景/目的：对于无法切除的局部晚期非小细胞肺癌（NSCLC）老年患者，在同步放化疗（CCRT）联合每日低剂量卡铂治疗后使用度伐利尤单抗巩固治疗的临床获益尚不清楚。
这是一项单机构回顾性队列研究。我们分析了2014年4月至2021年3月期间连续诊断为NSCLC并接受CCRT联合每日低剂量卡铂治疗的患者的病历。比较了总体组与两个亚组的结果：接受度伐利尤单抗巩固治疗的患者（CCRT-度伐利尤单抗组）和未接受的患者（单纯CCRT组）。主要终点为无进展生存期（PFS）和总生存期（OS）。
本研究共纳入38例患者（中位年龄：76岁）。总体组的中位PFS为9.9个月，CCRT-度伐利尤单抗组为11.7个月，单纯CCRT组为10.2个月。总体组的中位OS为39.4个月，CCRT-度伐利尤单抗组为32.0个月，单纯CCRT组为39.4个月。两个亚组在PFS方面[风险比（HR）=0.88，p=0.97]或OS方面（HR=1.21，p=0.70）无显著差异。
在现实世界中，对于无法切除的局部晚期NSCLC老年患者，CCRT联合每日低剂量卡铂治疗后使用度伐利尤单抗巩固治疗在PFS或OS方面似乎未带来临床获益。
